10 days ago
RLAY
AnalystsEtzer DaroutEtzer Darout's Stock Forecasts
AnalystsEtzer Darout
Sectors:
Analyst Ranking
Top 2%
#77 out of 5254 analysts
Average Return
+40.6%
Win Rate
58%98 out of 168
Risk vs Reward
Poor
Good
Etzer Darout's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Terns Pharmaceuticals IncTERN | +1,715.52% | $2.90 | $52.65 | 2025-05-12 - 2026-04-17 | Buy |
Five Prime Therapeutics IncFPRX | +884.42% | $3.85 | $37.90 | 2020-09-21 - 2021-03-09 | Strong Buy |
Terns Pharmaceuticals IncTERN | +614.59% | $7.40 | $52.88 | 2025-09-16 - 2026-03-30 | Strong Buy |
Terns Pharmaceuticals IncTERN | +549.63% | $8.14 | $52.88 | 2025-10-21 - 2026-03-30 | Strong Buy |
Scholar Rock Holding CorpSRRK | +278.17% | $8.45 | $31.96 | 2024-08-08 - 2025-08-08 | Buy |
Etzer Darout Analyst Color
Get additional color on Etzer Darout's coverage of popular stocks
11 days ago
ORKA
25 days ago
ABVX
a month ago
PTGX
a month ago
CTMX
a month ago
ORKA
a month ago
SRRK
a month ago
ANAB
2 months ago
CCCC
2 months ago
XNCR
2 months ago
IOVA
2 months ago
CTMX
3 months ago
CRVS
3 months ago
CTMX
3 months ago
ANAB
4 months ago
XNCR
4 months ago
SRRK
4 months ago
PTGX
4 months ago
IOVA
4 months ago
ARVN
4 months ago
KYMR
5 months ago
SNDX
5 months ago
KURA
5 months ago
IOVA
5 months ago
INCY
Etzer Darout's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Relay Therapeutics IncRLAY | 1 | Strong Buy | $21.00 | +25.30% | Maintains | 10 days ago |
Oruka Therapeutics IncORKA | 3 | Strong Buy | $78.00 | +13.17% | Maintains | 11 days ago |
Tvardi Therapeutics IncTVRD | 2 | Hold | $4.00 | +17.99% | Maintains | 17 days ago |
Terns Pharmaceuticals IncTERN | 12 | Hold | $53.00 | +0.66% | Downgrades | 19 days ago |
Abivax SaABVX | 2 | Strong Buy | $148.00 | +23.17% | Maintains | 25 days ago |
Protagonist Therapeutics IncPTGX | 7 | Strong Buy | $119.00 | +12.29% | Maintains | a month ago |
Cytomx Therapeutics IncCTMX | 13 | Strong Buy | $16.00 | +231.95% | Maintains | a month ago |
Biontech SeBNTX | 5 | Buy | $128.00 | +24.37% | Maintains | a month ago |
Macrogenics IncMGNX | 10 | Strong Buy | $4.00 | +15.61% | Maintains | a month ago |
Scholar Rock Holding CorpSRRK | 10 | Buy | $70.00 | +40.11% | Maintains | a month ago |
Anaptysbio IncANAB | 5 | Strong Buy | $79.00 | +17.02% | Maintains | a month ago |
C4 Therapeutics IncCCCC | 7 | Strong Buy | $7.00 | +139.73% | Maintains | 2 months ago |
Jazz Pharmaceuticals PLCJAZZ | 1 | Strong Buy | $224.00 | +10.12% | Initiates Coverage On | 2 months ago |
Xencor IncXNCR | 9 | Strong Buy | $27.00 | +106.74% | Maintains | 2 months ago |
Vir Biotechnology IncVIR | 1 | Strong Buy | $30.00 | +179.07% | Maintains | 2 months ago |
Iovance Biotherapeutics IncIOVA | 3 | Strong Buy | $11.00 | +184.97% | Maintains | 2 months ago |
Incyte CorpINCY | 3 | Strong Buy | $117.00 | +19.61% | Maintains | 2 months ago |
Exelixis IncEXEL | 6 | Hold | $44.00 | -1.98% | Maintains | 2 months ago |
Rapt Therapeutics IncRAPT | 4 | Hold | $58.00 | -0.03% | Downgrades | 3 months ago |
Corvus Pharmaceuticals IncCRVS | 2 | Strong Buy | $28.00 | +67.26% | Maintains | 3 months ago |
Janux Therapeutics IncJANX | 3 | Strong Buy | $29.00 | +83.31% | Maintains | 4 months ago |
Celldex Therapeutics IncCLDX | 3 | Strong Sell | $24.00 | -30.54% | Maintains | 4 months ago |
Arvinas IncARVN | 7 | Strong Buy | $18.00 | +63.64% | Maintains | 4 months ago |
Summit Therapeutics IncSMMT | 3 | Hold | $18.00 | -28.43% | Upgrades | 4 months ago |
Kymera Therapeutics IncKYMR | 4 | Strong Buy | $119.00 | +35.67% | Maintains | 4 months ago |
Syndax Pharmaceuticals IncSNDX | 1 | Strong Buy | $35.00 | +44.45% | Maintains | 5 months ago |
Kura Oncology IncKURA | 1 | Strong Buy | $28.00 | +189.26% | Maintains | 5 months ago |
Monopar TherapeuticsMNPR | 1 | Strong Buy | $125.00 | +122.34% | Initiates Coverage On | 6 months ago |
Merus NvMRUS | 8 | Hold | $97.00 | +7.78% | Downgrades | 7 months ago |
Inventiva SaIVA | 4 | Strong Buy | $13.00 | +129.28% | Maintains | 8 months ago |
Verve Therapeutics IncVERV | 1 | Strong Buy | $24.00 | N/A | Maintains | a year ago |
Q32 Bio IncQTTB | 3 | Hold | $3.00 | N/A | Downgrades | a year ago |
Igm Biosciences IncIGMS | 2 | Hold | $2.00 | N/A | Downgrades | a year ago |
Tourmaline Bio IncTRML | 1 | Buy | $50.00 | N/A | Initiates Coverage On | a year ago |
Nurix Therapeutics IncNRIX | 1 | Buy | $35.00 | N/A | Initiates Coverage On | a year ago |
Jasper Therapeutics IncJSPR | 1 | Buy | $63.00 | N/A | Initiates Coverage On | a year ago |
Acrivon Therapeutics IncACRV | 7 | Buy | $27.00 | N/A | Maintains | a year ago |
Nuvalent IncNUVL | 6 | Buy | $134.00 | N/A | Maintains | a year ago |
Genmab AGMAB | 3 | Buy | $48.00 | N/A | Reiterates | a year ago |
Novartis AgNVS | 3 | Hold | $120.00 | N/A | Maintains | a year ago |
Y Mabs Therapeutics IncYMAB | 5 | Buy | $25.00 | N/A | Maintains | 2 years ago |
Fate Therapeutics IncFATE | 7 | Hold | $6.00 | N/A | Maintains | 2 years ago |
Astrazeneca PLCAZN | 4 | Buy | $82.00 | N/A | Maintains | 2 years ago |
Immunogen IncIMGN | 4 | Hold | $31.00 | N/A | Downgrades | 2 years ago |
Foghorn Therapeutics IncFHTX | 2 | Buy | $19.00 | N/A | Maintains | 3 years ago |
Seagen IncSGEN | 4 | Hold | $229.00 | N/A | Downgrades | 3 years ago |
Alnylam Pharmaceuticals IncALNY | 2 | Strong Buy | $170.00 | N/A | Upgrades | 4 years ago |
Traws Pharma IncTRAW | 1 | Strong Buy | $60.00 | N/A | Initiates Coverage On | 5 years ago |
Five Prime Therapeutics IncFPRX | 2 | Hold | $38.00 | N/A | Downgrades | 5 years ago |
Akero Therapeutics IncAKRO | 1 | Strong Buy | $54.00 | N/A | Initiates Coverage On | 5 years ago |
Eidos Therapeutics IncEIDX | 2 | Hold | N/A | N/A | Downgrades | 6 years ago |
Mirum Pharmaceuticals IncMIRM | 1 | Strong Buy | $38.00 | N/A | Maintains | 6 years ago |
Aclaris Therapeutics IncACRS | 1 | Buy | $52.00 | N/A | Maintains | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.